[go: up one dir, main page]

WO2008003042A3 - Amnion-derived stem cells and uses thereof - Google Patents

Amnion-derived stem cells and uses thereof Download PDF

Info

Publication number
WO2008003042A3
WO2008003042A3 PCT/US2007/072356 US2007072356W WO2008003042A3 WO 2008003042 A3 WO2008003042 A3 WO 2008003042A3 US 2007072356 W US2007072356 W US 2007072356W WO 2008003042 A3 WO2008003042 A3 WO 2008003042A3
Authority
WO
WIPO (PCT)
Prior art keywords
amnion
stem cells
derived stem
adscs
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072356
Other languages
French (fr)
Other versions
WO2008003042A8 (en
WO2008003042A2 (en
Inventor
Dale Woodbury
Akiva J Marcus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Priority to EP07799131.3A priority Critical patent/EP2089510B1/en
Priority to US12/306,871 priority patent/US8980630B2/en
Publication of WO2008003042A2 publication Critical patent/WO2008003042A2/en
Publication of WO2008003042A8 publication Critical patent/WO2008003042A8/en
Publication of WO2008003042A3 publication Critical patent/WO2008003042A3/en
Anticipated expiration legal-status Critical
Priority to US14/660,572 priority patent/US10066202B2/en
Priority to US16/100,593 priority patent/US10407663B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs.
PCT/US2007/072356 2006-06-28 2007-06-28 Amnion-derived stem cells and uses thereof Ceased WO2008003042A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07799131.3A EP2089510B1 (en) 2006-06-28 2007-06-28 Amnion-derived stem cells and uses thereof
US12/306,871 US8980630B2 (en) 2006-06-28 2007-06-28 Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion
US14/660,572 US10066202B2 (en) 2006-06-28 2015-03-17 Method of cryopreserving an amniotic membrane of a placenta tissue sample
US16/100,593 US10407663B2 (en) 2006-06-28 2018-08-10 Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81698706P 2006-06-28 2006-06-28
US60/816,987 2006-06-28
US93078207P 2007-05-18 2007-05-18
US60/930,782 2007-05-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/306,871 A-371-Of-International US8980630B2 (en) 2006-06-28 2007-06-28 Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion
US14/660,572 Continuation US10066202B2 (en) 2006-06-28 2015-03-17 Method of cryopreserving an amniotic membrane of a placenta tissue sample

Publications (3)

Publication Number Publication Date
WO2008003042A2 WO2008003042A2 (en) 2008-01-03
WO2008003042A8 WO2008003042A8 (en) 2008-03-27
WO2008003042A3 true WO2008003042A3 (en) 2008-12-18

Family

ID=38846547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072356 Ceased WO2008003042A2 (en) 2006-06-28 2007-06-28 Amnion-derived stem cells and uses thereof

Country Status (3)

Country Link
US (3) US8980630B2 (en)
EP (1) EP2089510B1 (en)
WO (1) WO2008003042A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2664337B1 (en) 2005-09-27 2019-08-14 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
KR20200123283A (en) 2005-12-29 2020-10-28 안트로제네시스 코포레이션 Placental stem cell populations
US8980630B2 (en) 2006-06-28 2015-03-17 Rutgers, The State University Of New Jersey Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion
US10494607B2 (en) 2007-02-12 2019-12-03 Celularity, Inc. CD34+,CD45−placental stem cell-enriched cell populations
CA2677397C (en) 2007-02-12 2016-04-05 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
WO2008144820A1 (en) * 2007-05-28 2008-12-04 Monash University Treatment of chronic lung disease
RU2662676C1 (en) 2008-08-20 2018-07-26 Антродженезис Корпорейшн Improved cell composition and methods for its preparation
CN102176919A (en) 2008-08-22 2011-09-07 人类起源公司 Methods and compositions for treatment of bone defects with placental cell populations
CN102282252B (en) 2008-11-19 2017-07-04 人类起源公司 amnion derived adherent cells
CN102933221A (en) 2010-04-08 2013-02-13 人类起源公司 Treatment of sarcoidosis using placental stem cells
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US20120014932A1 (en) * 2010-07-14 2012-01-19 Golden William J Methods for treating disorders of amino acid metabolism
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN103687941A (en) * 2011-01-12 2014-03-26 城户常雄 Culture method for obtaining and maintaining a purified or enriched population of mammalian neural stem cells and/or neural progenitor cells amenable to differentiation into cells of the oligodendrocyte lineage in vitro
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
CA2847575C (en) * 2011-09-09 2021-10-19 Mesoblast, Inc. Method for increasing osteoblastic function
KR101906156B1 (en) * 2011-11-22 2018-10-12 주식회사 강스템바이오텍 Equine Amniotic Membrane-Derived Mesenchymal Stem Cells
WO2013085303A1 (en) * 2011-12-06 2013-06-13 주식회사 강스템홀딩스 Canine amniotic membrane-derived multipotent stem cells
WO2013091008A1 (en) * 2011-12-20 2013-06-27 The Mental Health Research Institute Of Victoria Method of treating reduced ceruloplasmin functionality in the central nervous system
CN104703572B (en) 2012-03-01 2017-07-04 安尼奥楚公司 Tissue for obtaining stem cell is reclaimed, stored and explant culture apparatus
EP2885001A4 (en) * 2012-08-16 2016-02-24 Stemnion Inc Novel cell compositions and methods
TW201603818A (en) 2014-06-03 2016-02-01 組織科技股份有限公司 Compositions and methods
US10342830B2 (en) 2015-01-05 2019-07-09 Gary M. Petrucci Methods and materials for treating lung disorders
TW201642914A (en) 2015-02-23 2016-12-16 組織科技股份有限公司 Apparatuses and methods for treating ophthalmic diseases and disorders
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
TW201733600A (en) 2016-01-29 2017-10-01 帝聖工業公司 Fetal support tissue products and methods of use
US10993969B2 (en) 2016-02-05 2021-05-04 Gary M. Petrucci Methods and materials for treating nerve injuries and neurological disorders
US10973953B1 (en) 2016-08-18 2021-04-13 Musculoskeletal Transplant Foundation Methods and compositions for preparing transplant tissue
CN106754685A (en) * 2017-01-17 2017-05-31 四川华皓生物科技有限公司 A kind of construction method of Human fat mesenchymal stem cell bank
US10478531B2 (en) 2017-06-22 2019-11-19 Gary M. Petrucci Methods and materials for treating blood vessels
US10251917B1 (en) 2017-09-19 2019-04-09 Gary M. Petrucci Methods and materials for treating tumors
KR102159630B1 (en) * 2018-11-06 2020-09-24 차의과학대학교 산학협력단 Pharmaceutical composition for preventing or treating cholestatic liver injury or hyperlipidemia comprising placenta-derived mesenchymal stem cells
CN109362714A (en) * 2018-12-18 2019-02-22 广州赛莱拉干细胞科技股份有限公司 A kind of adipose mesenchymal stem cell preservation solution and preparation method and application thereof
CN110973060B (en) * 2019-12-06 2021-10-22 武汉大学 An animal model of fetal-derived adult cholestatic liver injury, its specific biomarkers and its application
CN112608892B (en) * 2020-12-25 2023-11-14 深圳博雅感知药业有限公司 Method for serum-free separation and subculturing of umbilical cord mesenchymal stem cells by using platelet lysate
CN112841176A (en) * 2021-01-28 2021-05-28 暨南大学 Long-term cryopreservation medium for adipose-derived stem cells and preparation method and application thereof
WO2023080413A1 (en) * 2021-11-02 2023-05-11 주식회사 디자인셀 Stem cell culture and pharmaceutical composition comprising exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
CN114686426B (en) * 2022-03-24 2023-11-14 深圳市茵冠生物科技有限公司 Culture method and application of primary amniotic stem cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243172A1 (en) * 2006-04-12 2007-10-18 Rnl Bio Co., Ltd Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4860900A (en) * 1999-06-02 2000-12-18 Lifebank Services, L.L.C. Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20040161419A1 (en) 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
TWI338714B (en) * 2003-12-02 2011-03-11 Cathay General Hospital Method of isolation and enrichment of mesenchymal stem cells from amniotic fluid
GB0329449D0 (en) * 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
CA2577447C (en) 2004-08-16 2017-08-01 Cellresearch Corporation Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
US8980630B2 (en) 2006-06-28 2015-03-17 Rutgers, The State University Of New Jersey Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243172A1 (en) * 2006-04-12 2007-10-18 Rnl Bio Co., Ltd Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2089510A4 *

Also Published As

Publication number Publication date
US8980630B2 (en) 2015-03-17
US20190040355A1 (en) 2019-02-07
EP2089510A4 (en) 2010-05-19
US10407663B2 (en) 2019-09-10
US20150252325A1 (en) 2015-09-10
WO2008003042A8 (en) 2008-03-27
EP2089510B1 (en) 2021-02-24
WO2008003042A2 (en) 2008-01-03
EP2089510A2 (en) 2009-08-19
US10066202B2 (en) 2018-09-04
US20090238801A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2008003042A8 (en) Amnion-derived stem cells and uses thereof
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2007089798A3 (en) Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
WO2010021714A3 (en) Improved cell composition and methods of making the same
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
HRP20190220T1 (en) Anti-il-23 antibodies, compositions, methods and uses
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2008090340A3 (en) Nucleic acid amplification and testing
WO2008019148A3 (en) Tumor suppression using placental stem cells
WO2007047468A3 (en) Immunomodulation using placental stem cells
IL248917A0 (en) Human anti-il-23 antibodies,compositions, methods and uses
WO2008103935A3 (en) Novel tobacco compositions and methods of making
IL191771A0 (en) Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2005003320A3 (en) Neuronal differentiation of stem cells
WO2007136424A3 (en) Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
WO2006015209A3 (en) Differentiation of stem cells
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2007012695A3 (en) Tissue carbohydrate compositions and analysis thereof
WO2008070616A3 (en) METHODS AND COMPOSITIONS RELATED TO HIF-1α
WO2010039802A3 (en) Methods and compositions for isolating nucleic acid
WO2005121321A3 (en) Compositions comprising female germline stem cells and methods of use thereof
WO2007006870A3 (en) Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2010042551A3 (en) Methods for providing cellular lysates from cell wall-containing samples
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799131

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2007799131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12306871

Country of ref document: US